Refine by
Therapy System Articles & Analysis: Older
132 news found
Particles Plus® instruments have once again been used by scientists for research into Nebulizer Inhalation Therapy. To test the administration of safe Nebulizer Inhalation Therapy, researchers monitored particle concentrations for different particle sizes with Particles Plus® Optical Particle Counters (OPC). Optical Particle Counters can measure particle size distribution and particle ...
In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of treatment. ...
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
As a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. XPOVIO® is approved in mainland China for the following indication: In combination with dexamethasone for the ...
The ONWARD team has developed an epidural electrical stimulation system using electrodes placed in the epidural space (between the vertebrae and the spinal cord membrane), which has allowed subjects to walk again. ...
Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. ...
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of 16.7% in the 45 mg ...
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint ...
The FC1500 delivers constant charge power and eliminates the need for multiple power supplies in medical laser and Intense Pulsed Light Therapy (IPL) equipment. Conventional laser and IPL systems rely on capacitors that are charged to high voltages and then discharged to generate high-current pulses. By delivering 1500 W constant power over all charge voltages ...
AAV vectors are critical to gene therapy development. These vectors are the delivery system for inserting good genes into cells. ...
Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices BioIntelliSense, a continuous health monitoring and clinical intelligence company, ...
As a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. XPOVIO® is approved in mainland China for the following indication: In combination with dexamethasone for the ...
Today, the Baker-Polito Administration announced that more than $1.5 million has been awarded to four projects that seek to increase testing capacity and provide solutions for coronavirus testing. The funding is through the Accelerating Coronavirus Testing Solutions (A.C.T.S.) Program, designed and administered by the Massachusetts Life Sciences Center, which supports projects focused on two core ...
Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Myrtelle’s novel gene therapy for ...
Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition. ...
Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide ...
– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch® Ventricular Restoration System. ...
In an exciting report by ZDF, it is shown how CUREO can be used as a therapy method for Long Covid patients. In addition to acutely affected covid patients, many people struggle with the long-term consequences of the disease. These can be treated efficiently with CUREO. In addition to acutely affected Covid patients, many people also have to struggle with the long-term consequences of the virus. ...
H.U.B and NT have entered into an agreement whereby NT will deliver to H.U.B a complete nuBeam® BNCT treatment suite consisting of an accelerator-based neutron source and ancillary systems. The nuBeam® solution incorporates OncologyOne software developed by Cosylab, a proven partner with over two decades of experience solving complex software challenges in radiation ...